Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review

Abstract

Liver fibrosis could be the last hope for treating liver cancer and remodeling of the hepatic microenvironment has emerged as a strategy to promote the ablation of liver fibrosis. In recent years, especially with the rapid development of nanomedicine, hepatic microenvironment therapy has been widely researched in studies concerning liver cancer and fibrosis. In this comprehensive review, we summarized recent advances in nano therapy-based remodeling of the hepatic microenvironment. Firstly, we discussed novel strategies for regulatory immune suppression caused by capillarization of liver sinusoidal endothelial cells (LSECs) and macrophage polarization. Furthermore, metabolic reprogramming and extracellular matrix (ECM) deposition are caused by the activation of hepatic stellate cells (HSCs). In addition, recent advances in ROS, hypoxia, and impaired vascular remodeling in the hepatic fibrotic microenvironment due to ECM deposition have also been summarized. Finally, emerging nanotherapeutic approaches based on correlated signals were discussed in this review. We have proposed novel strategies such as engineered nanotherapeutics targeting antigen-presenting cells (APCs) or direct targeting T cells in liver fibrotic immunotherapy to be used in preventing liver fibrosis. In summary, this comprehensive review illustrated the opportunities in drug targeting and nanomedicine, and the current challenges to be addressed. Graphical Abstract

Bioresponsive Chimaeric Polymersomes Mediate Sustained and Liver-Specific siRNA Transfection In Vivo

“…Flow cytometry analysis results of the sorted liver cells displayed that the percentage of nonparenchymal cells (mainly Kupffer cells) that internalized with siApoB (Cy5) was much higher than that of hepatocytes (6.13 vs 1.12%) (Figure D). Hepatocytes accounting for 60–70% of the total liver cells and Kupffer cells accounting for 10–15% of the total liver cells , are the major cells for the internalization of nanoparticles. , This indicates that approximately half of the BCP- siApoB can be taken up by hepatocytes and the other half by Kupffer cells. Besides, to study the distribution of BCP- siApoB (Cy5) in the liver, the tissue slices were stained with fluorescent dyes.…”

Vessel co-option: a unique vascular-immune niche in liver cancer

“…They are irregular in shape and often extend several stellate processes around the hepatic sinusoids. HSCs can secrete chemokines, cytokines, growth factors, or proteases, which promote tumor growth, metastasis, angiogenesis, and immune escape, and are considered liver-specific pericytes (69)(70)(71)(72). Ming Qi et al found that in the CRCLM models of bevacizumab resistance, the HSCs around the co-option vessels had a high expression of fibroblast activation protein a (FAPa).…”

Hepatocytic Ballooning in Non-alcoholic Steatohepatitis: Bridging the Knowledge Gap and Charting Future Avenues

“…It highlights these cytokines as potential therapeutic targets for mitigating ballooning and its detrimental consequences. Understanding these inflammatory mediators and their interconnected pathways is crucial for unraveling the complexities of NASH and advancing targeted treatment strategies [ 44 ].…”